Skip to main content
SpringerLink
Log in

Development of a Pharmacokinetic Model to Describe the Complex Pharmacokinetics of Pazopanib in Cancer Patients

  • Original Research Article
  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

Abstract

Background and Objective

Pazopanib is a multi-targeted anticancer tyrosine kinase inhibitor. This study was conducted to develop a population pharmacokinetic (popPK) model describing the complex pharmacokinetics of pazopanib in cancer patients.

Methods

Pharmacokinetic data were available from 96 patients from three clinical studies. A multi-compartment model including (i) a complex absorption profile, (ii) the potential non-linear dose–concentration relationship and (iii) the potential long-term decrease in exposure was developed.

Results

A two-compartment model best described pazopanib pharmacokinetics. The absorption phase was modelled by two first-order processes: 36 % (relative standard error [RSE] 34 %) of the administered dose was absorbed with a relatively fast rate (0.4 h−1 [RSE 31 %]); after a lag time of 1.0 h (RSE 6 %), the remaining dose was absorbed at a slower rate (0.1 h−1 [RSE 28 %]). The relative bioavailability (rF) at a dose of 200 mg was fixed to 1. With an increasing dose, the rF was strongly reduced, which was modelled with an E max (maximum effect) model (E max was fixed to 1, the dose at half of maximum effect was estimated as 480 mg [RSE 23 %]). Interestingly, the plasma exposure to pazopanib also decreased over time, modelled on rF with a maximum magnitude of 50 % (RSE 27 %) and a first-order decay constant of 0.15 day−1 (RSE 43 %). The inter-patient and intra-patient variability on rF were estimated as 36 % (RSE 16 %) and 75 % (RSE 22 %), respectively.

Conclusion

A popPK model for pazopanib was developed that illustrated the complex absorption process, the non-linear dose–concentration relationship, the high inter-patient and intra-patient variability, and the first-order decay of pazopanib concentration over time. The developed popPK model can be used in clinical practice to screen covariates and guide therapeutic drug monitoring.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Votrient 200 mg film-coated tablets. Summary of product characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001141/WC500094272.pdf. Accessed 3 Sept 2015.

  2. Center for Drug Evaluation and Research. Clinical pharmacology and biopharmaceutics review(s) of Votrient. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022465s000_ClinPharmR.pdf. Accessed 13 Jan 2016.

  3. van Leeuwen RWF, van Gelder T, Mathijssen RHJ, Jansman FGA. Drug–drug interactions with tyrosine-kinase inhibitors: a clinical perspective. Lancet Oncol. 2014;15(8):e315–26.

    Article  PubMed  Google Scholar 

  4. Hurwitz HI, Dowlati A, Saini S, Savage S, Suttle AB, Gibson DM, et al. Phase I trial of pazopanib in patients with advanced cancer. Clin Cancer Res. 2009;15(12):4220–7.

    Article  CAS  PubMed  Google Scholar 

  5. de Wit D, van Erp NP, den Hartigh J, Wolterbeek R, den Hollander-van Deursen M, Labots M, et al. Therapeutic drug monitoring to individualize the dosing of pazopanib: a pharmacokinetic feasibility study. Ther Drug Monit. 2014;37(3):331–8.

    Article  Google Scholar 

  6. Suttle AB, Ball HA, Molimard M, Hutson TE, Carpenter C, Rajagopalan D, et al. Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma. Br J Cancer. 2014;111(10):1909–16.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Yu H, Steeghs N, Nijenhuis CM, Schellens JHM, Beijnen JH, Huitema ADR. Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: focus on the pharmacokinetic targets. Clin Pharmacokinet. 2014;53(4):305–25.

    Article  CAS  PubMed  Google Scholar 

  8. Yu H, Steeghs N, Kloth JSL, de Wit D, van Hasselt JGC, van Erp NP, et al. Integrated semi-physiological pharmacokinetic model for both sunitinib and its active metabolite SU12662. Br J Clin Pharmacol. 2015;79(5):809–19.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Kerbusch T, Huitema ADR, Ouwerkerk J, Keizer HJ, Mathôt RA, Schellens JHM, et al. Evaluation of the autoinduction of ifosfamide metabolism by a population pharmacokinetic approach using NONMEM. Br J Clin Pharmacol. 2000;49(6):555–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Kloth JSL, Klümpen H-J, Yu H, Eechoute K, Samer CF, Kam BLR, et al. Predictive value of CYP3A and ABCB1 phenotyping probes for the pharmacokinetics of sunitinib: the ClearSun study. Clin Pharmacokinet. 2014;53(3):261–9.

    Article  CAS  PubMed  Google Scholar 

  11. Diekstra MHM, Klümpen HJ, Lolkema MPJK, Yu H, Kloth JSL, Gelderblom H, et al. Association analysis of genetic polymorphisms in genes related to sunitinib pharmacokinetics, specifically clearance of sunitinib and SU12662. Clin Pharmacol Ther. 2014;96(1):81–9.

    Article  CAS  PubMed  Google Scholar 

  12. Gotta V, Widmer N, Montemurro M, Leyvraz S, Haouala A, Decosterd LA, et al. Therapeutic drug monitoring of imatinib: Bayesian and alternative methods to predict trough levels. Clin Pharmacokinet. 2012;51(3):187–201.

    Article  CAS  PubMed  Google Scholar 

  13. Hamberg P, Mathijssen RHJ, de Bruijn P, Leonowens C, van der Biessen D, Eskens FA, et al. Impact of pazopanib on docetaxel exposure: results of a phase I combination study with two different docetaxel schedules. Cancer Chemother Pharmacol. 2014;75(2):365–71.

    Article  PubMed  Google Scholar 

  14. Hamberg P, Boers-Sonderen MJ, van der Graaf WTA, de Bruijn P, Suttle AB, Eskens FALM, et al. Pazopanib exposure decreases as a result of an ifosfamide-dependent drug-drug interaction: results of a phase I study. Br J Cancer. 2014;110(4):888–93.

    Article  CAS  PubMed  Google Scholar 

  15. Imbs D-C, Négrier S, Cassier P, Hollebecque A, Varga A, Blanc E, et al. Pharmacokinetics of pazopanib administered in combination with bevacizumab. Cancer Chemother Pharmacol. 2014;73(6):1189–96.

    Article  CAS  PubMed  Google Scholar 

  16. Zhang L, Beal SL, Sheiner LB. Simultaneous vs. sequential analysis for population PK/PD data I: best-case performance. J Pharmacokinet Pharmacodyn. 2003;30(6):387–404.

    Article  PubMed  Google Scholar 

  17. Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 2011;13(2):143–51.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Beal SL, Boeckman AJ, Sheiner LB, editors. NONMEM user guides. San Francisco: University of Califomia at San Francisco; 1988.

    Google Scholar 

  19. Lindbom L, Pihlgren P, Jonsson EN, Jonsson N. PsN-Toolkit–a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed. 2005;79(3):241–57.

    Article  PubMed  Google Scholar 

  20. Keizer RJ, van Benten M, Beijnen JH, Schellens JHM, Huitema ADR. Piraña and PCluster: a modeling environment and cluster infrastructure for NONMEM. Comput Methods Programs Biomed. 2011;101(1):72–9.

    Article  PubMed  Google Scholar 

  21. R Development Core Team. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2008.

  22. Jonsson EN, Karlsson MO. Xpose–an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed. 1999;58(1):51–64.

    Article  CAS  PubMed  Google Scholar 

  23. The FDA Clinical Pharmacology and Biopharmaceutics Review(s) (application number 22-465) of Pazopanib (Votrient) (patient population Advanced Renal Cell Carcinoma). http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022465s000_ClinPharmR.pdf. Accessed 6 July 2016.

  24. Rowland M, Tozer TN. Chapter 7: absorption. Clinical pharmacokinetics and pharmacodynamics, 4th ed. Baltimore: Lippincott Williams & Wilkins; 2011. pp. 183–216.

  25. Imbs D-C, Diéras V, Bachelot T, Campone M, Isambert N, Joly F, et al. Pharmacokinetic interaction between pazopanib and cisplatin regimen. Cancer Chemother Pharmacol. 2016;77(2):385–92.

    Article  CAS  PubMed  Google Scholar 

  26. Eechoute K, Fransson MN, Reyners AK, De Jong FA, Sparreboom A, Van Der Graaf WTA, et al. A long-term prospective population pharmacokinetic study on imatinib plasma concentrations in GIST patients. Clin Cancer Res. 2012;18(20):5780–7.

    Article  CAS  PubMed  Google Scholar 

  27. Arrondeau J, Mir O, Boudou-Rouquette P, Coriat R, Ropert S, Dumas G, et al. Sorafenib exposure decreases over time in patients with hepatocellular carcinoma. Invest New Drugs. 2012;30(5):2046–9.

    Article  CAS  PubMed  Google Scholar 

  28. Goh BC, Reddy NJ, Dandamudi UB, Laubscher KH, Peckham T, Hodge JP, et al. An evaluation of the drug interaction potential of pazopanib, an oral vascular endothelial growth factor receptor tyrosine kinase inhibitor, using a modified Cooperstown 5 + 1 cocktail in patients with advanced solid tumors. Clin Pharmacol Ther. 2010;88(5):652–9.

    Article  CAS  PubMed  Google Scholar 

  29. Votrient: highlights of prescribing information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022465s-010S-012lbl.pdf. Accessed 3 Mar 2016.

  30. Verheijen RB, Bins S, Mathijssen RH, Lolkema M, van Doorn L, Schellens JH, et al. Individualized pazopanib dosing: a prospective feasibility study in cancer patients. Clin Cancer Res. 2016. [Epub ahead of print]

  31. Ahn JE, Birnbaum AK, Brundage RC. Inherent correlation between dose and clearance in therapeutic drug monitoring settings: possible misinterpretation in population pharmacokinetic analyses. J Pharmacokinet Pharmacodyn. 2005;32(5–6):703–18.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

We would like to thank Prof. Dr. Hans Gelderblom who was the principal investigator of Study 1. We would like to thank Prof. Dr. Stefan Sleijfer and Dr. Paul Hamberg who were the principal investigators of Studies 2 and 3. In addition, we would like to thank Remy Verheijen for useful discussions.

Author information

Authors and Affiliations

  1. Department of Pharmacy and Pharmacology, Netherlands Cancer Institute-Antoni van Leeuwenhoek and MC Slotervaart, Louwesweg 6, PO Box 90440, 1006 BK, Amsterdam, The Netherlands

    Huixin Yu, Jos H. Beijnen & Alwin D. R. Huitema

  2. Department of Clinical Pharmacy, Radboud University Medical Center, Nijmegen, The Netherlands

    Nielka van Erp

  3. Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands

    Sander Bins & Ron H. J. Mathijssen

  4. Department of Medical Oncology, Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, The Netherlands

    Jan H. M. Schellens & Neeltje Steeghs

  5. Department of Clinical Pharmacology, Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, The Netherlands

    Jan H. M. Schellens, Jos H. Beijnen, Neeltje Steeghs & Alwin D. R. Huitema

  6. Utrecht Institute of Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands

    Jan H. M. Schellens & Jos H. Beijnen

Authors
  1. Huixin Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nielka van Erp
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sander Bins
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ron H. J. Mathijssen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jan H. M. Schellens
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jos H. Beijnen
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Neeltje Steeghs
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Alwin D. R. Huitema
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Huixin Yu.

Ethics declarations

Funding

No sources of funding were used.

Conflict of interest

Huixin Yu, Nielka van Erp, Sander Bins, Ron Mathijssen, Jan Schellens, Jos Beijnen, Neeltje Steeghs and Alwin Huitema declare no conflicts of interest.

Electronic supplementary material

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yu, H., van Erp, N., Bins, S. et al. Development of a Pharmacokinetic Model to Describe the Complex Pharmacokinetics of Pazopanib in Cancer Patients. Clin Pharmacokinet 56, 293–303 (2017). https://doi.org/10.1007/s40262-016-0443-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40262-016-0443-y

Keywords

Search

Navigation